The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC 2018 | Immunogenetic-based approaches for prognostication in CLL
Kostas Stamatopoulos
• 31 Oct 2018
Immunogenetic-based approaches for prognostication in chronic lymphocytic leukemia (CLL) are discussed here by Kostas Stamatopoulos, MD, PhD, of the Center for Research and Technology Hellas, Thessaloniki, Greece, at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.
